Tag: orforglipron
-
Orforglipron (Foundayo): Clinical Evidence, Phase 3 Trials and FDA Approval
Approved by the US FDA on 1 April 2026 as Foundayo for chronic weight management, orforglipron is the first daily non-peptide oral GLP-1 receptor agonist taken without food or water restrictions. We examine its Phase 3 trial data, mechanisms and regulatory status.